These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 6602378)
1. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Bergmann SR; Fox KA; Ter-Pogossian MM; Sobel BE; Collen D Science; 1983 Jun; 220(4602):1181-3. PubMed ID: 6602378 [TBL] [Abstract][Full Text] [Related]
2. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. Van de Werf F; Ludbrook PA; Bergmann SR; Tiefenbrunn AJ; Fox KA; de Geest H; Verstraete M; Collen D; Sobel BE N Engl J Med; 1984 Mar; 310(10):609-13. PubMed ID: 6537987 [TBL] [Abstract][Full Text] [Related]
4. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Sobel BE; Geltman EM; Tiefenbrunn AJ; Jaffe AS; Spadaro JJ; Ter-Pogossian MM; Collen D; Ludbrook PA Circulation; 1984 May; 69(5):983-90. PubMed ID: 6608420 [TBL] [Abstract][Full Text] [Related]
5. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Van de Werf F; Bergmann SR; Fox KA; de Geest H; Hoyng CF; Sobel BE; Collen D Circulation; 1984 Mar; 69(3):605-10. PubMed ID: 6362907 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the recombinant Escherichia coli-produced protease domain of tissue-type plasminogen activator with alteplase, reteplase and streptokinase in a canine model of coronary artery thrombolysis. Martin U; Kohnert U; Stern A; Popp F; Fischer S Thromb Haemost; 1996 Dec; 76(6):1096-101. PubMed ID: 8972037 [TBL] [Abstract][Full Text] [Related]
9. Thrombolysis for evolving myocardial infarction. Health and Public Policy Committee, American College of Physicians. Ann Intern Med; 1985 Sep; 103(3):463-9. PubMed ID: 3161441 [No Abstract] [Full Text] [Related]
10. Thrombolysis with recombinant human single-chain urokinase-type plasminogen activator (rscu-PA): dose-response in dogs with coronary artery thrombosis. Van de Werf F; Jang IK; Collen D J Cardiovasc Pharmacol; 1987 Jan; 9(1):91-3. PubMed ID: 2434801 [TBL] [Abstract][Full Text] [Related]
11. An assessment of regional versus systemic thrombolytic treatment of peripheral and coronary artery thrombosis. Marder VJ; Francis CW Prog Hemost Thromb; 1984; 7():325-56. PubMed ID: 6241729 [No Abstract] [Full Text] [Related]
12. Encapsulation of a plasminogen activator speeds reperfusion, lessens infarct and reduces blood loss in a canine model of coronary artery thrombosis. Leach JK; Patterson E; O'Rear EA Thromb Haemost; 2004 Jun; 91(6):1213-8. PubMed ID: 15175809 [TBL] [Abstract][Full Text] [Related]
13. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594 [TBL] [Abstract][Full Text] [Related]
14. Direct intracoronary thrombolysis: treatment "a la mode". An alternative: the intravenous approach. Bernard R Acta Cardiol; 1983; 38(5):401-4. PubMed ID: 6606919 [No Abstract] [Full Text] [Related]
15. Thrombolytic therapy. A new strategy for the treatment of acute myocardial infarction (2). Laffel GL; Braunwald E N Engl J Med; 1984 Sep; 311(12):770-6. PubMed ID: 6236369 [No Abstract] [Full Text] [Related]
16. [Aspirin and heparin in the fibrinolytic treatment of acute myocardial infarction]. López Bescós L Rev Esp Cardiol; 1992; 45 Suppl 2():21-8. PubMed ID: 1475505 [TBL] [Abstract][Full Text] [Related]